Randie Raderman-Little
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Randie Raderman-Little has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
Curt L. Rohlfing
University of Missouri School of Medicine, Columbia, MO
19 shared publications- David B. Sacks
National Institutes of Health, Bethesda, MD, USA
13 shared publications David E Goldstein
Departments of Pathology & Anatomical Sciences and Child Health, University of Missouri-Columbia School of Medicine, Columbia, MO
9 shared publicationsDavid E. Goldstein
Departments of Pathology & Anatomical Sciences and Child Health, University of Missouri School of Medicine, Columbia, MO, USA
7 shared publicationsHsiao-Mei Wiedmeyer
Department of Pathology & Anatomical Sciences, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA
7 shared publicationsShawn Connolly
Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO
7 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 36, 1-8
MRM-based LC-MS method for accurate C-peptide quantitation
C-peptide secretion mirrors beta-cell function and has emerged as a valuable clinical biomarker for diabetes mellitus. C-peptide measurements can provide estimates of insulin secretory capacity, aiding in clinical decision-making and differentiation between diabetes types. Unfortunately, C-peptide assays are still not standardized, which may limit their practical clinical use. We have developed an MRM-based LC-MS method that demonstrated accuracy close to our reference method. To develop and validate a mass spectrometry method for accurate quantitation of C-peptide. A serum sample was spiked with isotope-labeled C-peptide as a standard. The enrichment process involved protein precipitation with methanol, solid-phase extraction, and anion exchange for C-peptide enrichment followed by Glu-C digestion. The peptide LGGGPGAGSLQPLALE was quantitated using MRM in positive ion mode. The calibration process includes C-peptide CRM material to ensure a complete traceability chain for the measurement. The assay exhibited linearity across a wide range of C-peptide concentrations and a limit of quantitation of 0.058 nmol/L. The inter-day imprecision was less than 9.6 % CV, and the intra-day imprecision was less than 8.9 % CV. Spiking with bilirubin, triglycerides, and hemoglobin demonstrated no interference, except for triglycerides at very high levels. The method exhibited a strong correlation to the C-peptide reference method (r2 = 0.95). The developed mass spectrometry method has demonstrated accurate results in C-peptide quantitation and can serve as a supplemental method to the existing C-peptide reference method. This ensures sustained stability over time and ultimately refines the existing reference system.
- 1 April 2025
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 36, 1-8
Open AccessMRM-based LC-MS method for accurate C-peptide quantitation
C-peptide secretion mirrors beta-cell function and has emerged as a valuable clinical biomarker for diabetes mellitus. C-peptide measurements can provide estimates of insulin secretory capacity, aiding in clinical decision-making and differentiation between diabetes types. Unfortunately, C-peptide assays are still not standardized, which may limit their practical clinical use. We have developed an MRM-based LC-MS method that demonstrated accuracy close to our reference method. To develop and validate a mass spectrometry method for accurate quantitation of C-peptide. A serum sample was spiked with isotope-labeled C-peptide as a standard. The enrichment process involved protein precipitation with methanol, solid-phase extraction, and anion exchange for C-peptide enrichment followed by Glu-C digestion. The peptide LGGGPGAGSLQPLALE was quantitated using MRM in positive ion mode. The calibration process includes C-peptide CRM material to ensure a complete traceability chain for the measurement. The assay exhibited linearity across a wide range of C-peptide concentrations and a limit of quantitation of 0.058 nmol/L. The inter-day imprecision was less than 9.6 % CV, and the intra-day imprecision was less than 8.9 % CV. Spiking with bilirubin, triglycerides, and hemoglobin demonstrated no interference, except for triglycerides at very high levels. The method exhibited a strong correlation to the C-peptide reference method (r2 = 0.95). The developed mass spectrometry method has demonstrated accurate results in C-peptide quantitation and can serve as a supplemental method to the existing C-peptide reference method. This ensures sustained stability over time and ultimately refines the existing reference system.
- 29 March 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (7) , 1104-1110
Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use
Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization of A1C testing was achieved, leading to high-quality results in clinical laboratories. We address the use of POC A1C testing in clinical situations and summarize the advantages and disadvantages of POC A1C testing. We emphasize the importance of considering the limitations of these devices and following correct testing procedures to ensure that accurate A1C results are obtained for optimal care of patients.
- 29 March 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (7) , 1104-1110
Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use
Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization of A1C testing was achieved, leading to high-quality results in clinical laboratories. We address the use of POC A1C testing in clinical situations and summarize the advantages and disadvantages of POC A1C testing. We emphasize the importance of considering the limitations of these devices and following correct testing procedures to ensure that accurate A1C results are obtained for optimal care of patients.
- 18 December 2023
- Published by ABCD Diabetes Care, Ltd. in British Journal of Diabetes
- Vol. 23 (2) , 105-113
When is HbA1c useful and what do the numbers mean – do they help or hinder?
Background: Glycated haemoglobin (HbA1c) measurement is used for diagnosis, management and remission of type 2 diabetes (T2DM), with measurements comparable worldwide and the World Health Organization listing medical conditions that affect its accuracy. Admission glucose is in the ‘diabetes’ range in 5% of emergency hospital admissions without prior diagnosis, with literature searches indicating inconsistent practice on using HbA1c to confirm diagnosis. As oral glucose tolerance tests (OGTT) were not possible during the COVID-19 pandemic, guidance was issued by the Royal College of Obstetrics and Gynaecology on using HbA1c for gestational diabetes mellitus. Aims: This study explores use of HbA1c at Queen Elizabeth Hospital Birmingham, a large university hospital serving a multi- ethnic adult population. Methods: Information is presented on comparability, clinical audits, research studies and current practice, and is illustrated by case reports. Results: Data from the National Glycohemoglobin Standardization Program show comparability of laboratoryHbA1c and point-of-care testing methods from 1993 to 2023. Although HbA1c was used to diagnose gestational diabetes during the COVID-19 pandemic, hospitals have reverted to OGTT post pandemic. In contrast, HbA1c is now being used to assess T2DM remission. Case reports illustrate these scenarios and highlight the complexity of decision-making when the accuracy of the HbA1c reading is affected by multiple co- morbidities. Conclusions: This wider use of HbA1c includes remission of T2DM but the diagnosis of gestational diabetes has reverted to OGTT post pandemic. A pictorial representation of HbA1c range is presented to aid understanding of this test. It is suitable for diagnosis of diabetes in most people except those with some variant haemoglobins or abnormal red blood cell turnover.
- 18 December 2023
- Published by ABCD Diabetes Care, Ltd. in British Journal of Diabetes
- Vol. 23 (2) , 105-113
When is HbA1c useful and what do the numbers mean – do they help or hinder?
Background: Glycated haemoglobin (HbA1c) measurement is used for diagnosis, management and remission of type 2 diabetes (T2DM), with measurements comparable worldwide and the World Health Organization listing medical conditions that affect its accuracy. Admission glucose is in the ‘diabetes’ range in 5% of emergency hospital admissions without prior diagnosis, with literature searches indicating inconsistent practice on using HbA1c to confirm diagnosis. As oral glucose tolerance tests (OGTT) were not possible during the COVID-19 pandemic, guidance was issued by the Royal College of Obstetrics and Gynaecology on using HbA1c for gestational diabetes mellitus. Aims: This study explores use of HbA1c at Queen Elizabeth Hospital Birmingham, a large university hospital serving a multi- ethnic adult population. Methods: Information is presented on comparability, clinical audits, research studies and current practice, and is illustrated by case reports. Results: Data from the National Glycohemoglobin Standardization Program show comparability of laboratoryHbA1c and point-of-care testing methods from 1993 to 2023. Although HbA1c was used to diagnose gestational diabetes during the COVID-19 pandemic, hospitals have reverted to OGTT post pandemic. In contrast, HbA1c is now being used to assess T2DM remission. Case reports illustrate these scenarios and highlight the complexity of decision-making when the accuracy of the HbA1c reading is affected by multiple co- morbidities. Conclusions: This wider use of HbA1c includes remission of T2DM but the diagnosis of gestational diabetes has reverted to OGTT post pandemic. A pictorial representation of HbA1c range is presented to aid understanding of this test. It is suitable for diagnosis of diabetes in most people except those with some variant haemoglobins or abnormal red blood cell turnover.
- 5 July 2023
- Published by Cold Spring Harbor Laboratory
- Vol. 69 (7) , 687-688
Commentary on Abnormal Hb A1c Result from a Diabetic Patient Leads to Unexpected Diagnosis
- 5 July 2023
- Published by Cold Spring Harbor Laboratory
- Vol. 69 (7) , 687-688
Commentary on Abnormal Hb A1c Result from a Diabetic Patient Leads to Unexpected Diagnosis
- Open Access
- 17 November 2021
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 22, 79-80
Comments on Deng, et al: The potential for Isotope dilution-LC-MS/MS to improve laboratory measurement of c-peptide; reasons and critical determinants
- 17 November 2021
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 22, 79-80
Open AccessComments on Deng, et al: The potential for Isotope dilution-LC-MS/MS to improve laboratory measurement of c-peptide; reasons and critical determinants
- 11 August 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (10) , 2379-2387
Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease
OBJECTIVE In chronic kidney disease, glycated albumin and fructosamine have been postulated to be better biomarkers of glycemic control than HbA1c. We evaluated the accuracy, variability, and covariate bias of three biomarkers (HbA1c, glycated albumin, and fructosamine) compared with continuous glucose monitoring (CGM)–derived measurement of glycemia across estimated glomerular filtration rate (eGFR) in type 2 diabetes. RESEARCH DESIGN AND METHODS A prospective cohort study was conducted of 104 participants with type 2 diabetes, 80 with eGFR 2 (not treated with dialysis) and 24 frequency-matched control subjects with eGFR ≥60 mL/min/1.73 m2. Participants wore a blinded CGM for two 6-day periods separated by 2 weeks, with blood and urine collected at the end of each CGM period. HbA1c, glycated albumin, and fructosamine were measured by high-performance liquid chromatographic, enzymatic, and colorimetric nitroblue tetrazolium methods, respectively. RESULTS Within-person biomarker values were strongly correlated between the two CGM periods (r = 0.92–0.95), although no marker fully captured the within-person variability of mean CGM glucose. All markers were similarly correlated with mean CGM glucose (r = 0.71–77). Compared with mean CGM glucose, glycated albumin and fructosamine were significantly biased by age, BMI, serum iron concentration, transferrin saturation, and albuminuria; HbA1c was underestimated in those with albuminuria. CONCLUSIONS Glycated albumin and fructosamine were not less variable than HbA1c at a given mean CGM glucose level, with several additional sources of bias. These results support measuring HbA1c to monitor trends in glycemia among patients with eGFR 2. Direct measurements of glucose are necessary to capture short-term variability.
- 11 August 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (10) , 2379-2387
Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease
OBJECTIVE In chronic kidney disease, glycated albumin and fructosamine have been postulated to be better biomarkers of glycemic control than HbA1c. We evaluated the accuracy, variability, and covariate bias of three biomarkers (HbA1c, glycated albumin, and fructosamine) compared with continuous glucose monitoring (CGM)–derived measurement of glycemia across estimated glomerular filtration rate (eGFR) in type 2 diabetes. RESEARCH DESIGN AND METHODS A prospective cohort study was conducted of 104 participants with type 2 diabetes, 80 with eGFR 2 (not treated with dialysis) and 24 frequency-matched control subjects with eGFR ≥60 mL/min/1.73 m2. Participants wore a blinded CGM for two 6-day periods separated by 2 weeks, with blood and urine collected at the end of each CGM period. HbA1c, glycated albumin, and fructosamine were measured by high-performance liquid chromatographic, enzymatic, and colorimetric nitroblue tetrazolium methods, respectively. RESULTS Within-person biomarker values were strongly correlated between the two CGM periods (r = 0.92–0.95), although no marker fully captured the within-person variability of mean CGM glucose. All markers were similarly correlated with mean CGM glucose (r = 0.71–77). Compared with mean CGM glucose, glycated albumin and fructosamine were significantly biased by age, BMI, serum iron concentration, transferrin saturation, and albuminuria; HbA1c was underestimated in those with albuminuria. CONCLUSIONS Glycated albumin and fructosamine were not less variable than HbA1c at a given mean CGM glucose level, with several additional sources of bias. These results support measuring HbA1c to monitor trends in glycemia among patients with eGFR 2. Direct measurements of glucose are necessary to capture short-term variability.
- Top Cited PapersOpen Access
- 1 July 2019
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 65 (7) , 839-848
The National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin A1c Measurement
BACKGROUND: Measurement of hemoglobin A1c (HbA1c) in the blood is integral to and essential for the treatment of patients with diabetes mellitus. HbA1c reflects the mean blood glucose concentration over the preceding 8 to 12 weeks. Although the clinical value of HbA1c was initially limited by large differences in results among various methods, the investment of considerable effort to implement standardization has brought about a marked improvement in analysis. CONTENT: The focus of this review is on the substantial progress that has been achieved in enhancing the accuracy and, therefore, the clinical value of HbA1c assays. SUMMARY: The interactions between the National Glycohemoglobin Standardization Program and manufacturers of HbA1c methods have been instrumental in standardizing HbA1c. Proficiency testing using whole blood has allowed accuracy-based assessment of methods in individual clinical laboratories that has made an important contribution to improving the HbA1c measurement in patient samples. These initiatives, supported by the efforts of the IFCC network, have led to a continuing enhancement of HbA1c methods. Many of the factors that previously influenced HbA1c results independently of blood glucose have been eliminated from most modern methods. These include carbamylation, labile intermediates, and common hemoglobin variants. Nevertheless, some factors (e.g., race and aging) may alter HbA1c interpretation, but whether these differences have clinical implications remains contentious. HbA1c has a fundamental role in the diagnosis and management of diabetes. Ongoing improvements in HbA1c measurement and quality will further enhance the clinical value of this analyte.
- 1 July 2019
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 65 (7) , 839-848
Top Cited PapersOpen AccessThe National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin A1c Measurement
BACKGROUND: Measurement of hemoglobin A1c (HbA1c) in the blood is integral to and essential for the treatment of patients with diabetes mellitus. HbA1c reflects the mean blood glucose concentration over the preceding 8 to 12 weeks. Although the clinical value of HbA1c was initially limited by large differences in results among various methods, the investment of considerable effort to implement standardization has brought about a marked improvement in analysis. CONTENT: The focus of this review is on the substantial progress that has been achieved in enhancing the accuracy and, therefore, the clinical value of HbA1c assays. SUMMARY: The interactions between the National Glycohemoglobin Standardization Program and manufacturers of HbA1c methods have been instrumental in standardizing HbA1c. Proficiency testing using whole blood has allowed accuracy-based assessment of methods in individual clinical laboratories that has made an important contribution to improving the HbA1c measurement in patient samples. These initiatives, supported by the efforts of the IFCC network, have led to a continuing enhancement of HbA1c methods. Many of the factors that previously influenced HbA1c results independently of blood glucose have been eliminated from most modern methods. These include carbamylation, labile intermediates, and common hemoglobin variants. Nevertheless, some factors (e.g., race and aging) may alter HbA1c interpretation, but whether these differences have clinical implications remains contentious. HbA1c has a fundamental role in the diagnosis and management of diabetes. Ongoing improvements in HbA1c measurement and quality will further enhance the clinical value of this analyte.
- Open Access
- 1 December 2017
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (12) , 1904-1905
Implementing a Reference Measurement System for C-Peptide: An Addendum
To the Editor: In a recent study by Little et al. (1), the story of C-peptide standardization was left somewhat uncertain with the problem of 2 reference methods providing different C-peptide concentrations. Although very well correlated ( r 2 = 0.986), there was a bias of approximately 20% between the Diabetes Diagnostic Laboratory (DDL)1 method (operated in 2 different laboratories in the US) and the National Metrology Institute of Japan (NMIJ; y = 0.7824x − 0.0202). There were differences in the procedures and in the labeled internal standards (ISs). The NMIJ method was traceable to the NMIJ Certified Reference Material (6901-b) (2), whereas the DDL method was traceable to the IS developed in Dr. Stein's Laboratory in …
- 1 December 2017
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (12) , 1904-1905
Open AccessImplementing a Reference Measurement System for C-Peptide: An Addendum
To the Editor: In a recent study by Little et al. (1), the story of C-peptide standardization was left somewhat uncertain with the problem of 2 reference methods providing different C-peptide concentrations. Although very well correlated ( r 2 = 0.986), there was a bias of approximately 20% between the Diabetes Diagnostic Laboratory (DDL)1 method (operated in 2 different laboratories in the US) and the National Metrology Institute of Japan (NMIJ; y = 0.7824x − 0.0202). There were differences in the procedures and in the labeled internal standards (ISs). The NMIJ method was traceable to the NMIJ Certified Reference Material (6901-b) (2), whereas the DDL method was traceable to the IS developed in Dr. Stein's Laboratory in …
- Open Access
- 1 December 2017
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (12) , 1901-1902
Prevalence of Rare Hemoglobin Variants Identified During Measurements of Hb A1c by Capillary Electrophoresis
- 1 December 2017
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (12) , 1901-1902
Open AccessPrevalence of Rare Hemoglobin Variants Identified During Measurements of Hb A1c by Capillary Electrophoresis
- Open Access
- 12 September 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 40 (10) , e149
Comment on Lewis et al. Management of Hemoglobin Variants Detected Incidentally in HbA1c Testing: A Common Problem Currently Lacking a Standard Approach. Diabetes Care 2017;40:e8–e9
We read with concern the article by Lewis et al. (1) regarding HbA1c analysis in the Vitamin D and Type 2 Diabetes (D2d) Study. Although the article focused on reporting the presence of hemoglobin (Hb) variants after incidental detection of variants by HbA1c high-performance liquid chromatography (HPLC) methods, there was also clear mention of a lack of interference from HbS and HbC with the HbA1c assay used for the study—the Tosoh G8 HPLC. Unfortunately, although the authors claim that there is no interference of these common Hb variants with the Tosoh G8 method, there is clear evidence to the contrary. Our study (2) clearly showed a statistically and clinically significant bias in results from this …
- 12 September 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 40 (10) , e149
Open AccessComment on Lewis et al. Management of Hemoglobin Variants Detected Incidentally in HbA1c Testing: A Common Problem Currently Lacking a Standard Approach. Diabetes Care 2017;40:e8–e9
We read with concern the article by Lewis et al. (1) regarding HbA1c analysis in the Vitamin D and Type 2 Diabetes (D2d) Study. Although the article focused on reporting the presence of hemoglobin (Hb) variants after incidental detection of variants by HbA1c high-performance liquid chromatography (HPLC) methods, there was also clear mention of a lack of interference from HbS and HbC with the HbA1c assay used for the study—the Tosoh G8 HPLC. Unfortunately, although the authors claim that there is no interference of these common Hb variants with the Tosoh G8 method, there is clear evidence to the contrary. Our study (2) clearly showed a statistically and clinically significant bias in results from this …